Conventional external-beam radiation therapy is dedicated to the treatment of localized
disease, whereas radioimmunotherapy represents an innovative tool for the treatment of …

This review focuses on the use of radiolabeled antibodies in the therapy of cancer, termed
radioimmunotherapy (RAIT). Basic problems concerning the choice of antibody and …

With the approval of 2 radiolabeled antibody products for the treatment of non-Hodgkin's
lymphoma (NHL), radioimmunotherapy (RIT) has finally come of age as a new therapeutic …

A valuable resource for researchers and workers in the fields of both pharmaceuticals and
biotechnology as well as undergraduates in biochemistry, applied biology, biomedical …

Radioimmunotherapy (RIT) represents an attractive tool for the treatment of local and/or
diffuse tumors with radiation. In RIT, cytotoxic radionuclides are delivered by monoclonal …

There are currently 6 unconjugated antibodies and 3 immunoconjugates approved for use in
the United States in a variety of cancers, with a considerable number of new agents in …

We retrospectively evaluated 18F-FDG PET/CT for monitoring the response of non-
Hodgkin's lymphoma to radioimmunotherapy. Methods: A total of 33 clinical patients …

A novel, facile procedure for efficient coupling of high doses of 131I to monoclonal
antibodies (MAbs) was developed with minimal chemical and radiation damage. Methods …

Radioimmunotherapy (RIT) is currently being considered for the treatment of solid tumors.
Although results have been encouraging for pretargeted 131I RIT with the affinity …

Objectives. Epithelial ovarian cancer (EOC) is known to produce carcinoembryonic antigen
(CEA), and the plasma CEA level is frequently elevated in patients with advanced stage and …